ClinicalTrials.gg
CompletedNCT02915159Updated Aug 10, 2020Results posted

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

A Phase 3 interventional study of Abatacept and Placebo in Sjogrens Disease, sponsored by Bristol-Myers Squibb. Completed at 71 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-10.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy of abatacept compared to placebo in patients with Sjögren's Syndrome.

02

Conditions studied

  • Sjogrens Disease
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score of at least 5
  • Positive anti-SS-A/Ro antibody at screening
  • meet the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism Classification Criteria for Sjögren's Syndrome (EULAR SS)

Exclusion criteria

Exclusion Criteria:

  • Secondary Sjögrens syndrome
  • Active life-threatening or organ-threatening complications of Sjögren's-syndrome
  • Other medical condition associated with sicca syndrome

Other protocol defined inclusion/exclusion criteria could apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    Abatacept

    Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months

    Biological: Abatacept

  • Placebo comparator
    Placebo

    Placebo for Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months

    Biological: Abatacept · Other: Placebo

Interventions

  • BiologicalAbatacept

    Also known as: Orencia, Bristol-Myers Squibb (BMS)-188667

  • OtherPlacebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)

    The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity (DA), Low = Low DA, Moderate = Moderate DA, High = High DA) Overall score, which can range from 0 to 123, a higher score indicates more disease activity

    Time frame: Day 169

Secondary outcomes

  1. Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Inde (ESSPRI)

    The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.

    Time frame: Day 169

  2. Change From Baseline in the Stimulated Whole Salivary Flow

    The mean change from baseline in the stimulated whole salivary flow at Day 169

    Time frame: Day 169

  3. Change From Baseline of DAS28-C-reactive Peptide (CRP): In The Full Population

    The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  4. Change From Baseline of DAS28-CRP: Tender Swollen Joint Count of at Least 3

    The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  5. Change From Baseline of DAS28-CRP: Tender Swollen Joints Count Less Than 3

    The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  6. Change From Baseline in the Joint Component of DAS28-CRP: In the Full Population

    The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  7. Change From Baseline in the CRP Component of DAS28-CRP: In the Full Population

    The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  8. Change From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: In the Full Population

    The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  9. Change From Baseline in the Joint Component of DAS28-CRP: Tender Swollen Joints of at Least 3

    The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  10. Change From Baseline in the CRP Component of DAS28-CRP: Tender Swollen Joints of at Least 3

    The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  11. Change From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: Tender Swollen Joints of at Least 3

    The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  12. Change From Baseline in the Joint Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3

    The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  13. Change From Baseline in the CRP Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3

    The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  14. Change From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3

    The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  15. Participants Who Achieve Minimally Clinically Important Change in ESSDAI in at Least 3 Points

    Proportion of participants who achieve a minimally clinically important change (of at least 3 points) in the ESSDAI at all measured time points up to Day 169.

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  16. Participants Who Achieve Minimally Clinically Important Change in ESSDAI in at Least 5 Points

    Proportion of participants who achieve a minimally clinically important change (of at least 5 points) in the ESSDAI at all measured time points up to Day 169.

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  17. Participants Who Achieve Minimally Clinically Important Change in ESSPRI in at Least 1 Point

    Proportion of participants who achieve a minimally clinically important change (of at least 1 point) in the ESSPRI at all measured time points up to Day 169.

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  18. Change From Baseline at All Measured Time Points in the ESSDAI

    The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity (DA), Low = Low DA, Moderate = Moderate DA, High = High DA) Overall score, which can range from 0 to 123, a higher score indicates more disease activity

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  19. Change From Baseline at All Measured Time Points in the ESSPRI

    The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  20. Change From Baseline in Components of ESSDAI

    The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score for activity level) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity, Low = Low Disease Activity, Moderate = Moderate Disease Activity, High = High Disease Activity)

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141 and Day 169

  21. Change From Baseline in ESSPRI Components

    The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.

    Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

  22. Change From Baseline in Schirmer's Test

    The Mean change from baseline in Schirmer's Test at all measured time points up to day 169 The length in millimeters that the strip wets during the 5 minute test period for each eye. Collection is done separately for each eye.

    Time frame: Day 85, Day 169

  23. Change From Baseline in the Ocular Staining Score (OSS)

    The Mean change from baseline in OSS at all measured time points up to day 169 Score of 0 = No Staining Score of 12 = diffuse staining The total score will be calculated as the sum of the score for these parameters for each eye. Medial Nasal Bulbar Conjunctiva (MNBC) \[score scale: 0 - 3\], Corneal (CORN) Staining of Punctate Epithelial Erosions (PEE) \[score scale: 0 - 3\], Lateral Temporal Bulbar Conjunctiva (LTBC) \[score scale: 0 - 3\], Patches of Confluent Staining (CONF) \[score scale: 0 - 1\], PEE observed in the pupil region, i.e. central 4mm diameter portion of the cornea (PUPL) \[score scale: 0 - 1\], one of more filaments seen anywhere on the cornea (FILA) \[score scale: 0 - 1\]

    Time frame: Day 85, Day 169

  24. Change From Baseline in Tear Break-up Time

    The Mean change from baseline in Tear Break-up Time at all measured time points up to day 169 The CRF collects the time in seconds to first appearance of a random dry spot on the corneal surface for 3 repetitions in each eye. The average time will calculated for each eye averaging the 3 measurements for each eye separately. In case only 2 measurements are available, the average of the 2 measurements will be calculated. In case there is only 1 measurement, that measurement will be used for the analysis.

    Time frame: Day 85, Day 169

  25. Change From Baseline in Unstimulated Salivary Flow

    The mean change from baseline in unstimulated whole salivary flow at all measured time points up to Day 169.

    Time frame: Day 85, Day 169

  26. Change From Baseline in Stimulated Salivary Flow

    The mean change from baseline in Stimulated whole salivary flow at all measured time points up to Day 169.

    Time frame: Day 85, Day 169

  27. Change From Baseline in Numeric Rating Scale for Mouth Dryness

    The mean change from baseline in participant symptoms using the Numeric Rating Scale (NRS) for mouth dryness at all measured time points up to Day 169. The oral and ocular dryness are each assessed by the patients with numeric rating scales from 0 to 10 with 0 representing no dryness and 10 representing maximal dryness

    Time frame: Day 1, 29, 57, 85, 113, 141, 169

  28. Change From Baseline in Numeric Rating Scale for Eye Dryness

    The mean change from baseline in patient symptoms using the Numeric Rating Scale (NRS) for eye dryness at all measured time points up to Day 169. The oral and ocular dryness are each assessed by the patients with numeric rating scales from 0 to 10 with 0 representing no dryness and 10 representing maximal dryness

    Time frame: Day 1, 29, 57, 85, 113, 141, 169

  29. Change From Baseline in Participant Assessment of Disease Activity

    The participant global assessment of disease activity are assessed with visual analog scales. The participant marks a vertical line through a horizontal line, where the beginning of the horizontal line represents the best situation, and the end of the horizontal line represents the very worst situation. The CRF collects the distance in millimeters from the start of the scale that is marked as well as the length of the scale in millimeters. In cases that the length of the scale is in less or more than 100 millimeters, then the participants measurement will be rescaled to the equivalent of 100 millimeters using the formula below: Rescale Measurement in mm = (measurement as reported on CRF in mm/length of the line on CRF in mm) \* 100mm A negative score = participant assessment of disease activity has improved A positive score = participant assessment of disease activity has worsened

    Time frame: Day 29, 57, 85, 113, 141, 169

  30. Change From Baseline in Physician Global Assessment of Disease Activity

    The physician global assessment of disease activity are assessed with visual analog scales. The physician marks a vertical line through a horizontal line, where the beginning of the horizontal line represents the best situation, and the end of the horizontal line represents the very worst situation. The CRF collects the distance in millimeters from the start of the scale that is marked as well as the length of the scale in millimeters. In cases that the length of the scale is in less or more than 100 millimeters, then the participants measurement will be rescaled to the equivalent of 100 millimeters using the formula below: Rescale Measurement in mm = (measurement as reported on CRF in mm/length of the line on CRF in mm) \* 100mm A negative score = physician assessment of disease activity has improved A positive score = physician assessment of disease activity has worsened

    Time frame: Day 29, 57, 85, 113, 141, 169

  31. Change From Baseline in Patient Fatigue

    The mean change from baseline in patient fatigue using Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue assessment of disease activity at all measured time points up to Day 169. PROMIS Fatigue instruments 10 Questions ranging from a score 0 to 40. Sum of the values gives you the raw sum. The raw is inputted into this formula to give you the raw score: Raw Score = (Raw sum\*number of items on the short form)/(Number of items that were actually answered) Raw score is translated to a T-Score using a table. T-Score is used as the final score. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. The standardized T-score is reported as the final score for each participant. A negative T Score = Better Prognosis A positive T Score = Worse prognosis

    Time frame: Day 29, 57, 85, 113, 141, 169

  32. Change From Baseline in Female Sexual Function Using the Female Sexual Function Index (FSFI)

    For the FSFI, is a 19 item instrument used for assessing key dimensions of female sexual function over the past 4 weeks with 6 domains being analyzed. The specific domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) analyzed in the FSFI are scored on a scale ranging from 0 to 5, with higher scores indicating better performance. Domain scores are calculated by summing the scores of the individual questions that make up the domain and multiplying the sum by the factor in the table below. The full scale score is the sum of the six domain scores. Full Scale Score range: 2.0(minimum score) - 36.0 (maximum score) Negative Score = Reduced functioning Positive Score = Improved functioning

    Time frame: Day 85, Day 169

  33. Change From Baseline in 36-item Short Form Health Survey (SF-36)

    The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement

    Time frame: Day 85, Day 169

  34. Geometric Mean of Trough Concentration (Cmin) of Abatacept

    Geometric mean of trough concentration (Cmin) of abatacept at all measured time points.

    Time frame: Day 29, 85, 113, 141, 169

  35. Percentage of Participants With a Positive Antibody Response

    Percentage of participants with at least one positive immunogenicity response up to Day 169 and during 3 months follow up (for participants who discontinue during the 6-months double-blind).

    Time frame: Day 85 db, day 169 db, post treatment day 85

  36. Summary of Adverse Events: Double Blind Period

    Percentage of participants with adverse events, deaths, serious adverse events and adverse events leading to discontinuation

    Time frame: Day 1 up to first dose of Open Label Treatment Period (OLTP) abatacept or up to 56 post last dose in double -blind for those not in OL.

  37. Laboratory Marked Abnormalities: Double Blind Period

    Laboratory values meeting the marked abnormality criteria

    Time frame: Day 1 up to first dose of OL abatacept or up to 56 post last dose in double -blind for those not in OL.

  38. Percentage of Participants With a Positive Antibody Response in the Cumulative Abatacept Period

    Percentage of participants with at least one positive immunogenicity response On Day 365 (end of Open label treatment period) and day 85 post open label follow up period.

    Time frame: Day 365, post open label treatment day 85

  39. Summary of Adverse Events: Cumulative Abatacept Period

    Percentage of participants with adverse events, deaths, serious adverse events and adverse events leading to discontinuation

    Time frame: Day 365 and 3 months of follow up approximately 450 Days

  40. Laboratory Marked Abnormalities: Cumulative Abatacept Period

    Laboratory values meeting the marked abnormality criteria

    Time frame: Day 365 and 3 months of follow up approximately 450 Days

07

Results

Posted Jan 2, 2020

Participant flow

Participant flow — Overall Study
MilestoneAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Started9295
Completed8187
Not completed118
Withdrew: Participant no longer meets criteria20
Withdrew: Poor/non-compliance10
Withdrew: Participant withdrew consent51
Withdrew: Request to discontinue treatment12
Withdrew: Adverse event22
Withdrew: Lack of efficacy03

Outcome measures

PrimaryChange From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity (DA), Low = Low DA, Moderate = Moderate DA, High = High DA) Overall score, which can range from 0 to 123, a higher score indicates more disease activity

Time frame:
Day 169
Reported as:
Mean · Score on a Scale
Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)-3.2 (-4.6 to -1.9)-3.7 (-5.0 to -2.4)
Statistical analysis
  • Abatacept - Double Blind Treatment Period vs Placebo - Double Blind Treatment Period · longitudinal repeated measures analysis · p = 0.4421
SecondaryChange From Baseline in EULAR Sjogren's Syndrome Patient Reported Inde (ESSPRI)

The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.

Time frame:
Day 169
Reported as:
Mean · Score on a Scale
Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Inde (ESSPRI)
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Inde (ESSPRI)-1.26 (-1.88 to -0.64)-1.52 (-2.12 to -0.93)
Statistical analysis
  • Abatacept - Double Blind Treatment Period vs Placebo - Double Blind Treatment Period · longitudinal repeated measures analysis · p = 0.3367
SecondaryChange From Baseline in the Stimulated Whole Salivary Flow

The mean change from baseline in the stimulated whole salivary flow at Day 169

Time frame:
Day 169
Reported as:
Mean · mL/min
Change From Baseline in the Stimulated Whole Salivary Flow
mL/minAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Change From Baseline in the Stimulated Whole Salivary Flow0.057 (-0.115 to 0.230)0.108 (-0.060 to 0.276)
Statistical analysis
  • Abatacept - Double Blind Treatment Period vs Placebo - Double Blind Treatment Period · longitudinal repeated measures analysis · p = .5841
SecondaryChange From Baseline of DAS28-C-reactive Peptide (CRP): In The Full Population

The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Scores on a scale
Change From Baseline of DAS28-C-reactive Peptide (CRP): In The Full Population
Scores on a scaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-0.4 (-0.6 to -0.2)-0.4 (-0.6 to -0.2)
Day 57-0.6 (-0.8 to -0.4)-0.7 (-0.9 to -0.4)
Day 85-0.8 (-1.0 to -0.6)-0.8 (-1.1 to -0.6)
Day 113-0.8 (-1.0 to -0.5)-1.0 (-1.2 to -0.7)
Day 141-0.8 (-1.0 to -0.5)-1.0 (-1.3 to -0.8)
Day 169-0.9 (-1.1 to -0.6)-1.1 (-1.4 to -0.9)
SecondaryChange From Baseline of DAS28-CRP: Tender Swollen Joint Count of at Least 3

The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Scores on a scale
Change From Baseline of DAS28-CRP: Tender Swollen Joint Count of at Least 3
Scores on a scaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-0.5 (-0.8 to -0.2)-0.6 (-0.9 to -0.3)
Day 57-0.9 (-1.2 to -0.5)-1.0 (-1.3 to -0.6)
Day 85-1.1 (-1.5 to -0.7)-1.2 (-1.5 to -0.8)
Day 113-1.1 (-1.4 to -0.7)-1.4 (-1.7 to -1.0)
Day 141-1.2 (-1.5 to -0.8)-1.5 (-1.8 to -1.1)
Day 169-1.3 (-1.7 to -0.9)-1.5 (-1.9 to -1.2)
SecondaryChange From Baseline of DAS28-CRP: Tender Swollen Joints Count Less Than 3

The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Scores on a scale
Change From Baseline of DAS28-CRP: Tender Swollen Joints Count Less Than 3
Scores on a scaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-0.3 (-0.6 to 0.0)-0.2 (-0.6 to 0.1)
Day 57-0.2 (-0.5 to 0.1)-0.2 (-0.5 to 0.1)
Day 85-0.4 (-0.6 to -0.1)-0.4 (-0.7 to -0.1)
Day 113-0.3 (-0.6 to -0.0)-0.3 (-0.6 to -0.1)
Day 141-0.2 (-0.5 to 0.1)-0.4 (-0.7 to -0.0)
Day 169-0.3 (-0.5 to -0.0)-0.5 (-0.7 to -0.2)
SecondaryChange From Baseline in the Joint Component of DAS28-CRP: In the Full Population

The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Joint Count
Change From Baseline in the Joint Component of DAS28-CRP: In the Full Population
Joint CountAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29 - Tender Joint-1.7 (-2.8 to -0.7)-1.9 (-2.9 to -0.8)
Day 29 - Swollen Joint-0.5 (-1.0 to 0.1)-0.6 (-1.1 to -0.1)
Day 57 - Tender Joint-2.6 (-3.7 to -1.5)-2.9 (-4.0 to -1.9)
Day 57 - Swollen Joint-1.0 (-1.6 to -0.3)-1.0 (-1.6 to -0.4)
Day 85 - Tender Joint-2.9 (-4.1 to -1.7)-3.4 (-4.6 to -2.2)
Day 85 - Swollen Joint-1.4 (-2.0 to -0.8)-1.4 (-2.0 to -0.9)
Day 113 - Tender Joint-3.1 (-4.2 to -2.0)-3.9 (-5.0 to -2.8)
Day 113 - Swollen Joint-1.5 (-2.0 to -1.1)-1.9 (-2.3 to -1.4)
Day 141 - Tender Joint-3.6 (-4.7 to -2.5)-4.1 (-5.2 to -3.0)
Day 141 - Swollen Joint-1.4 (-1.9 to -0.8)-1.8 (-2.4 to -1.3)
Day 169 - Tender Joint-2.9 (-4.0 to -1.7)-4.4 (-5.6 to -3.3)
Day 169 - Swollen Joint-1.4 (-1.9 to -0.8)-2.0 (-2.6 to -1.5)
SecondaryChange From Baseline in the CRP Component of DAS28-CRP: In the Full Population

The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · mg/L
Change From Baseline in the CRP Component of DAS28-CRP: In the Full Population
mg/LAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29 - CRP0.3 (-1.4 to 2.0)0.6 (-1.0 to 2.3)
Day 57 - CRP-0.1 (-2.1 to 1.8)1.8 (-0.1 to 3.6)
Day 85 - CRP-0.2 (-5.0 to 4.5)3.0 (-1.6 to 7.6)
Day 113 - CRP1.6 (-0.8 to 4.1)0.3 (-2.1 to 2.6)
Day 141 - CRP3.5 (-1.7 to 8.8)-0.2 (-5.2 to 4.7)
Day 169 - CRP-0.2 (-1.8 to 1.3)0.0 (-1.5 to 1.5)
SecondaryChange From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: In the Full Population

The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Scores on a Scale
Change From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: In the Full Population
Scores on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29 - Assessment of Disease Activity-4.0 (-9.8 to 1.7)-7.1 (-12.7 to -1.4)
Day 57 - Assessment of Disease Activity-7.5 (-13.4 to -1.7)-6.3 (-11.9 to -0.6)
Day 85 - Assessment of Disease Activity-10.4 (-16.3 to -4.4)-10.2 (-16.0 to -4.4)
Day 113 - Assessment of Disease Activity-8.0 (-14.0 to -2.0)-9.7 (-15.5 to -3.9)
Day 141 - Assessment of Disease Activity-5.1 (-11.0 to 0.8)-11.0 (-16.7 to -5.3)
Day 169 - Assessment of Disease Activity-10.1 (-16.1 to -4.0)-9.0 (-14.8 to -3.1)
SecondaryChange From Baseline in the Joint Component of DAS28-CRP: Tender Swollen Joints of at Least 3

The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Joint Count
Change From Baseline in the Joint Component of DAS28-CRP: Tender Swollen Joints of at Least 3
Joint CountAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29 - Tender Joint-2.8 (-4.5 to -1.0)-3.0 (-4.7 to -1.3)
Day 29 - Swollen Joint-0.7 (-1.5 to 0.2)-0.9 (-1.7 to -0.1)
Day 57 - Tender Joint-4.1 (-5.9 to -2.3)-4.8 (-6.5 to -3.0)
Day 57 - Swollen Joint-1.5 (-2.6 to -0.5)-1.6 (-2.6 to -0.5)
Day 85 - Tender Joint-4.4 (-6.3 to -2.4)-5.4 (-7.2 to -3.6)
Day 85 - Swollen Joint-2.1 (-3.1 to -1.1)-2.2 (-3.2 to -1.3)
Day 113 - Tender Joint-4.8 (-6.6 to -2.9)-6.0 (-7.7 to -4.2)
Day 113 - Swollen Joint-2.3 (-3.2 to -1.5)-2.9 (-3.7 to -2.2)
Day 141 - Tender Joint-5.7 (-7.5 to -3.8)-6.4 (-8.2 to -4.7)
Day 141 - Swollen Joint-2.2 (-3.1 to -1.3)-3.0 (-3.8 to -2.1)
Day 169 - Tender Joint-4.6 (-6.5 to -2.7)-6.7 (-8.5 to -4.9)
Day 169 - Swollen Joint-2.2 (-3.1 to -1.3)-3.1 (-4.0 to -2.3)
SecondaryChange From Baseline in the CRP Component of DAS28-CRP: Tender Swollen Joints of at Least 3

The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · mg/L
Change From Baseline in the CRP Component of DAS28-CRP: Tender Swollen Joints of at Least 3
mg/LAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29 - CRP-1.5 (-3.7 to 0.7)-0.7 (-2.8 to 1.4)
Day 57 - CRP-1.3 (-4.3 to 1.7)1.3 (-1.5 to 4.0)
Day 85 - CRP-2.2 (-9.8 to 5.5)3.8 (-3.4 to 11.0)
Day 113 - CRP1.2 (-2.7 to 5.1)-0.4 (-4.0 to 3.2)
Day 141 - CRP4.5 (-4.0 to 12.9)-1.4 (-9.0 to 6.3)
Day 169 - CRP-1.4 (-3.9 to 1.1)-0.7 (-3.0 to 1.6)
SecondaryChange From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: Tender Swollen Joints of at Least 3

The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Score on a Scale
Change From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: Tender Swollen Joints of at Least 3
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29 - Assessment of Disease Activity0.6 (-6.9 to 8.1)-3.5 (-10.7 to 3.7)
Day 57 - Assessment of Disease Activity-3.5 (-11.5 to 4.5)-6.5 (-14.0 to 1.1)
Day 85 - Assessment of Disease Activity-7.5 (-15.5 to 0.4)-7.7 (-15.3 to -0.1)
Day 113 - Assessment of Disease Activity-6.6 (-14.4 to 1.3)-9.1 (-16.5 to -1.6)
Day 141 - Assessment of Disease Activity-1.2 (-9.0 to 6.7)-8.1 (-15.5 to -0.7)
Day 169 - Assessment of Disease Activity-6.7 (-14.9 to 1.5)-7.8 (-15.5 to -0.0)
SecondaryChange From Baseline in the Joint Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3

The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Joint Count
Change From Baseline in the Joint Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3
Joint CountAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29 - Tender Joint-0.1 (-0.9 to 0.6)-0.2 (-0.9 to 0.6)
Day 29 - Swollen Joint0.1 (-0.2 to 0.3)0.1 (-0.2 to 0.4)
Day 57 - Tender Joint-0.2 (-0.9 to 0.6)0.1 (-0.6 to 0.9)
Day 57 - Swollen Joint0.2 (-0.1 to 0.4)0.0 (-0.2 to 0.3)
Day 85 - Tender Joint-0.5 (-1.3 to 0.2)0.1 (-0.7 to 0.8)
Day 85 - Swollen Joint-0.0 (-0.3 to 0.2)0.1 (-0.2 to 0.4)
Day 113 - Tender Joint-0.4 (-1.2 to 0.3)-0.5 (-1.3 to 0.3)
Day 113 - Swollen Joint0.0 (-0.3 to 0.3)0.1 (-0.2 to 0.4)
Day 141 - Tender Joint-0.2 (-1.0 to 0.6)-0.2 (-1.0 to 0.6)
Day 141 - Swollen Joint0.2 (-0.1 to 0.5)0.3 (0.0 to 0.6)
Day 169 - Tender Joint-0.1 (-0.9 to 0.7)-0.7 (-1.4 to 0.1)
Day 169 - Swollen Joint0.2 (-0.1 to 0.5)-0.0 (-0.3 to 0.2)
SecondaryChange From Baseline in the CRP Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3

The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · mg/L
Change From Baseline in the CRP Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3
mg/LAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29 - CRP2.1 (-0.8 to 4.9)1.8 (-1.2 to 4.7)
Day 57 - CRP0.5 (-2.3 to 3.4)1.0 (-1.9 to 3.9)
Day 85 - CRP1.4 (-1.5 to 4.3)0.1 (-2.8 to 3.1)
Day 113 - CRP1.3 (-1.6 to 4.1)0.1 (-2.8 to 3.1)
Day 141 - CRP0.7 (-2.2 to 3.6)0.8 (-2.1 to 3.8)
Day 169 - CRP0.2 (-2.7 to 3.1)0.2 (-2.8 to 3.1)
SecondaryChange From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3

The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Scores on a Scale
Change From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3
Scores on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29 - Assessment of Disease Activity-10.3 (-19.3 to -1.4)-11.8 (-21.3 to -2.3)
Day 57 - Assessment of Disease Activity-12.4 (-21.4 to -3.4)-4.8 (-14.3 to 4.7)
Day 85 - Assessment of Disease Activity-14.0 (-23.0 to -5.0)-13.5 (-23.0 to -4.0)
Day 113 - Assessment of Disease Activity-9.1 (-18.1 to -0.0)-11.1 (-20.6 to -1.5)
Day 141 - Assessment of Disease Activity-10.6 (-19.8 to -1.5)-15.3 (-24.8 to -5.7)
Day 169 - Assessment of Disease Activity-13.8 (-23.0 to -4.6)-10.9 (-20.5 to -1.4)
SecondaryParticipants Who Achieve Minimally Clinically Important Change in ESSDAI in at Least 3 Points

Proportion of participants who achieve a minimally clinically important change (of at least 3 points) in the ESSDAI at all measured time points up to Day 169.

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Number · Percentage
Participants Who Achieve Minimally Clinically Important Change in ESSDAI in at Least 3 Points
PercentageAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 2937 (27.1 to 47.7)34.7 (25.3 to 45.2)
Day 5737 (27.1 to 47.7)44.2 (34.0 to 54.8)
Day 8548.9 (38.3 to 59.6)50.5 (40.1 to 60.9)
Day 11355.4 (44.7 to 65.8)50.5 (40.1 to 60.9)
Day 14151.1 (40.4 to 61.7)56.8 (46.3 to 67.0)
Day 16955.4 (44.7 to 65.8)57.9 (47.3 to 68.0)
SecondaryParticipants Who Achieve Minimally Clinically Important Change in ESSDAI in at Least 5 Points

Proportion of participants who achieve a minimally clinically important change (of at least 5 points) in the ESSDAI at all measured time points up to Day 169.

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Number · Percentage
Participants Who Achieve Minimally Clinically Important Change in ESSDAI in at Least 5 Points
PercentageAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 2919.6 (12.0 to 29.1)13.7 (7.5 to 22.3)
Day 5726.1 (17.5 to 36.3)24.2 (16.0 to 34.1)
Day 8534.8 (25.1 to 45.4)32.6 (23.4 to 43.0)
Day 11337.0 (27.1 to 47.7)36.8 (27.2 to 47.4)
Day 14137.0 (27.1 to 47.7)36.8 (31.1 to 51.6)
Day 16935.9 (26.1 to 46.5)46.3 (36.0 to 56.8)
SecondaryParticipants Who Achieve Minimally Clinically Important Change in ESSPRI in at Least 1 Point

Proportion of participants who achieve a minimally clinically important change (of at least 1 point) in the ESSPRI at all measured time points up to Day 169.

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Number · Percentage
Participants Who Achieve Minimally Clinically Important Change in ESSPRI in at Least 1 Point
PercentageAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 2931.5 (22.2 to 42.0)38.9 (29.1 to 49.5)
Day 5742.4 (32.1 to 53.1)47.4 (37.0 to 57.9)
Day 8544.6 (34.2 to 55.3)55.8 (45.2 to 66.0)
Day 11342.4 (32.1 to 53.1)52.6 (42.1 to 63.0)
Day 14140.2 (30.1 to 51.0)54.7 (44.2 to 65.0)
Day 16941.3 (31.1 to 52.1)52.6 (42.1 to 63.0)
SecondaryChange From Baseline at All Measured Time Points in the ESSDAI

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity (DA), Low = Low DA, Moderate = Moderate DA, High = High DA) Overall score, which can range from 0 to 123, a higher score indicates more disease activity

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Percent Change from Baseline
Change From Baseline at All Measured Time Points in the ESSDAI
Percent Change from BaselineAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-10.9 (-22.3 to 0.54)-12.6 (-23.71 to -1.39)
Day 57-24.1 (-36.10 to -12.08)-18.9 (-30.52 to -7.32)
Day 85-26.0 (-38.81 to -13.17)-25.4 (-37.76 to -13.01)
Day 113-34.1 (-46.8 to -21.34)-32.1 (-44.35 to -19.83)
Day 141-29.7 (-43.02 to -16.31)-37.0 (-49.81 to -24.12)
Day 169-33.4 (-46.54 to -20.24)-37.6 (-50.24 to -25.02)
SecondaryChange From Baseline at All Measured Time Points in the ESSPRI

The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Score on a Scale
Change From Baseline at All Measured Time Points in the ESSPRI
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-0.32 (-0.79 to 0.16)-0.54 (-1.00 to -0.08)
Day 57-0.81 (-1.32 to -0.31)-0.82 (-1.31 to -0.33)
Day 85-0.83 (-1.34 to -0.32)-1.20 (-1.70 to -0.70)
Day 113-0.79 (-1.32 to -0.26)-1.37 (-1.88 to -0.86)
Day 141-0.87 (-1.40 to -0.35)-1.32 (-1.83 to -0.81)
Day 169-1.03 (-1.55 to -0.50)-1.30 (-1.80 to -0.79)
SecondaryChange From Baseline in Components of ESSDAI

The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score for activity level) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity, Low = Low Disease Activity, Moderate = Moderate Disease Activity, High = High Disease Activity)

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141 and Day 169
Reported as:
Mean · Score on a Scale
Change From Baseline in Components of ESSDAI
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29: Constitutional-0.3 (-0.4 to -0.1)-0.4 (-0.5 to -0.2)
Day 29: Lymphadenopathy-0.6 (-1.0 to -0.2)-0.5 (-0.9 to -0.2)
Day 29: Glandular-0.2 (-0.4 to 0.0)-0.2 (-0.4 to 0.0)
Day 29: Articular-0.4 (-0.8 to 0.0)-0.3 (-0.7 to 0.1)
Day 29: Cutaneous-0.3 (-0.6 to -0.0)-0.2 (-0.5 to 0.1)
Day 29: Pulmonary0.0 (-0.3 to 0.3)0.1 (-0.2 to 0.4)
Day 29: Renal-0.0 (-0.2 to 0.2)-0.2 (-0.3 to 0.0)
Day 29: Muscular-0.0 (-0.1 to 0.1)-0.0 (-0.1 to 0.1)
Day 29: Peripheral Nervous System-0.0 (-0.2 to 0.2)0.0 (-0.2 to 0.20)
Day 29: Haematogical0.2 (-0.0 to 0.4)0.1 (-0.1 to 0.4)
Day 29: Biological0.1 (-0.1 to 0.2)0.1 (-0.0 to 0.3)
Day 57: Constitutional-0.2 (-0.4 to -0.0)-0.3 (-0.5 to -0.1)
Day 57: Lymphadenopathy-0.7 (-1.1 to -0.2)-0.6 (-1.0 to -0.2)
Day 57: Glandular-0.4 (-0.7 to -0.2)-0.4 (-0.6 to -0.1)
Day 57: Articular-0.7 (-1.1 to -0.3)-0.8 (-1.2 to -0.4)
Day 57: Cutaneous-0.3 (-0.6 to -0.0)-0.2 (-0.5 to 0.1)
Day 57: Pulmonary-0.0 (-0.3 to 0.3)0.2 (-0.1 to 0.5)
Day 57: Renal-0.0 (-0.2 to 0.2)-0.1 (-0.3 to 0.1)
Day 57: Muscular-0.0 (-0.1 to 0.1)-0.1 (-0.2 to -0.0)
Day 57: Peripheral Nervous System-0.0 (-0.2 to 0.2)0.0 (-0.2 to 0.2)
Day 57: Haematological0.1 (-0.1 to 0.4)0.2 (-0.0 to 0.4)
Day 57: Biological-0.1 (-0.2 to 0.1)0.0 (-0.1 to 0.2)
Day 85: Constitutional-0.3 (-0.5 to -0.1)-0.4 (-0.6 to -0.2)
Day 85: Lymphadenopathy-0.7 (-1.1 to -0.3)-0.8 (-1.2 to -0.4)
Day 85: Glandular-0.4 (-0.6 to -0.1)-0.5 (-0.7 to -0.2)
Day 85: Articular-1.0 (-1.5 to -0.6)-1.1 (-1.6 to -0.7)
Day 85: Cutaneous-0.4 (-0.7 to -0.0)-0.2 (-0.5 to 0.1)
Day 85: Pulmonary0.0 (-0.3 to 0.4)0.2 (-0.1 to 0.5)
Day 85: Renal-0.1 (-0.3 to 0.1)-0.1 (-0.3 to 0.1)
Day 85: Muscular-0.1 (-0.2 to 0.0)-0.0 (-0.1 to 0.1)
Day 85: Peripheral Nervous System-0.0 (-0.2 to 0.2)0.0 (-0.2 to 0.2)
Day 85: Haematological0.1 (-0.1 to 0.3)0.2 (-0.1 to 0.4)
Day 85: Biological0.0 (-0.1 to 0.2)0.2 (0.0 to 0.3)
Day 113: Constitutional-0.3 (-0.5 to -0.0)-0.3 (-0.5 to -0.1)
Day 113: Lymphadenopathy-0.8 (-1.2 to -0.4)-0.9 (-1.3 to -0.5)
Day 113: Glandular-0.5 (-0.7 to -0.3)-0.5 (-0.8 to -0.3)
Day 113: Articular-1.3 (-1.8 to -0.8)-1.3 (-1.7 to -0.8)
Day 113: Cutaneous-0.4 (-0.7 to -0.1)-0.4 (-0.7 to -0.1)
Day 113: Pulmonary0.0 (-0.3 to 0.4)0.1 (-0.2 to 0.5)
Day 113: Renal-0.1 (-0.3 to 0.1)0.0 (-0.2 to 0.2)
Day 113: Muscular-0.0 (-0.1 to 0.1)-0.1 (-0.2 to 0.0)
Day 113: Peripheral Nervous System-0.0 (-0.2 to 0.2)-0.0 (-0.2 to 0.1)
Day 113: Haematological0.1 (-0.2 to 0.3)0.2 (-0.0 to 0.4)
Day 113: Biological-0.0 (-0.2 to 0.1)0.1 (-0.0 to 0.3)
Day 141: Constitutional-0.2 (-0.4 to 0.0)-0.4 (-0.6 to -0.2)
Day 141: Lymphadenopathy-0.6 (-1.1 to -0.2)-0.9 (-1.4 to -0.5)
Day 141: Glandular-0.5 (-0.7 to -0.2)-0.6 (-0.8 to -0.4)
Day 141: Articular-1.2 (-1.7 to -0.8)-1.4 (-1.9 to -1.0)
Day 141: Cutaneous-0.4 (-0.7 to -0.1)-0.5 (-0.8 to -0.3)
Day 141: Pulmonary-0.0 (-0.4 to 0.3)0.1 (-0.2 to 0.4)
Day 141: Renal-0.0 (-0.2 to 0.2)-0.1 (-0.3 to 0.1)
Day 141: Muscular-0.1 (-0.2 to 0.0)-0.1 (-0.2 to 0.0)
Day 141: Peripheral Nervous System-0.1 (-0.3 to 0.1)-0.0 (-0.2 to 0.1)
Day 141: Haematological0.1 (-0.1 to 0.4)0.1 (-0.1 to 0.4)
Day 141: Biological-0.0 (-0.2 to 0.1)0.1 (-0.0 to 0.2)
Day 169: Constitutional-0.3 (-0.5 to -0.1)-0.4 (-0.6 to -0.2)
Day 169: Lymphadenopathy-0.9 (-1.3 to -0.5)-1.1 (-1.4 to -0.7)
Day 169: Glandular-0.4 (-0.6 to -0.1)-0.5 (-0.8 to -0.3)
Day 169: Articular-1.4 (-1.8 to -0.9)-1.8 (-2.2 to -1.4)
Day 169: Cutaneous-0.3 (-0.7 to 0.0)-0.5 (-0.9 to -0.2)
Day 169: Pulmonary-0.0 (-0.4 to 0.3)0.1 (-0.2 to 0.4)
Day 169: Renal-0.0 (-0.2 to 0.2)0.0 (-0.2 to 0.2)
Day 169: Muscular-0.0 (-0.1 to 0.1)-0.1 (-0.2 to 0.0)
Day 169: Peripheral Nervous-0.1 (-0.3 to 0.1)-0.0 (-0.2 to 0.2)
Day 169: Haematological0.1 (-0.2 to 0.3)0.3 (0.1 to 0.5)
Day 169: Biological0.0 (-0.1 to 0.2)0.2 (0.0 to 0.3)
SecondaryChange From Baseline in ESSPRI Components

The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.

Time frame:
Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Score on a Scale
Change From Baseline in ESSPRI Components
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29: Dryness Score-0.21 (-0.76 to 0.34)-0.26 (-0.80 to 0.28)
Day 29: Fatigue Score-0.57 (-1.18 to 0.03)-1.01 (-1.60 to -0.42)
Day 29: Pain Score-0.34 (-0.96 to 0.27)-0.53 (-1.13 to 0.07)
Day 57: Dryness Score-0.92 (-1.51 to -0.33)-0.52 (-1.09 to 0.05)
Day 57: Fatigue Score-1.09 (-1.70 to -0.48)-1.22 (-1.81 to -0.63)
Day 57: Pain Score-0.60 (-1.24 to 0.05)-0.90 (-1.52 to -0.27)
Day 85: Dryness Score-0.68 (-1.25 to -0.11)-0.91 (-1.46 to -0.36)
Day 85: Fatigue Score-1.27 (-1.91 to -0.63)-1.56 (-2.18 to -0.94)
Day 85: Pain Score-0.70 (-1.35 to -0.05)-1.31 (-1.93 to -0.68)
Day 113: Dryness Score-0.74 (-1.36 to -0.12)-1.19 (-1.79 to -0.60)
Day 113: Fatigue Score-1.02 (-1.65 to -0.39)-1.76 (-2.37 to -1.15)
Day 113: Pain Score-0.76 (-1.40 to -0.11)-1.37 (-1.99 to -0.74)
Day 141: Dryness Score-0.89 (-1.49 to -0.28)-1.05 (-1.63 to -0.46)
Day 141: Fatigue Score-1.18 (-1.83 to -0.53)-1.73 (-2.36 to -1.11)
Day 141: Pain Score-0.70 (-1.34 to -0.07)-1.39 (-2.00 to -0.78)
Day 169: Dryness Score-0.84 (-1.46 to -0.23)-1.04 (-1.63 to -0.44)
Day 169: Fatigue Score-1.28 (-1.93 to -0.64)-1.57 (-2.19 to -0.95)
Day 169: Pain Score-1.11 (-1.75 to -0.47)-1.45 (-2.06 to -0.83)
SecondaryChange From Baseline in Schirmer's Test

The Mean change from baseline in Schirmer's Test at all measured time points up to day 169 The length in millimeters that the strip wets during the 5 minute test period for each eye. Collection is done separately for each eye.

Time frame:
Day 85, Day 169
Reported as:
Mean · millimeters
Change From Baseline in Schirmer's Test
millimetersAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 85: Study Eye1.9 (-0.0 to 3.9)1.5 (-0.5 to 3.5)
Day 85: Non-Study Eye0.1 (-2.0 to 2.2)0.8 (-1.2 to 2.9)
Day 85: Average of Both Eyes1.10 (-0.75 to 2.96)1.41 (-0.43 to 3.24)
Day 169: Study Eye1.7 (-0.4 to 3.9)1.0 (-1.1 to 3.2)
Day 169: Non-Study Eye0.6 (-1.3 to 2.4)0.2 (-1.7 to 2.1)
Day 169: Average of Both Eyes1.21 (-0.59 to 3.00)0.82 (-0.97 to 2.61)
SecondaryChange From Baseline in the Ocular Staining Score (OSS)

The Mean change from baseline in OSS at all measured time points up to day 169 Score of 0 = No Staining Score of 12 = diffuse staining The total score will be calculated as the sum of the score for these parameters for each eye. Medial Nasal Bulbar Conjunctiva (MNBC) \[score scale: 0 - 3\], Corneal (CORN) Staining of Punctate Epithelial Erosions (PEE) \[score scale: 0 - 3\], Lateral Temporal Bulbar Conjunctiva (LTBC) \[score scale: 0 - 3\], Patches of Confluent Staining (CONF) \[score scale: 0 - 1\], PEE observed in the pupil region, i.e. central 4mm diameter portion of the cornea (PUPL) \[score scale: 0 - 1\], one of more filaments seen anywhere on the cornea (FILA) \[score scale: 0 - 1\]

Time frame:
Day 85, Day 169
Reported as:
Mean · Score on a Scale
Change From Baseline in the Ocular Staining Score (OSS)
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 85: Study Eye-1.7 (-2.5 to -0.9)-0.5 (-1.3 to 0.3)
Day 85: Non-Study Eye-0.6 (-1.4 to 0.2)0.4 (-0.4 to 1.2)
Day 85: Average of Both Eyes-1.15 (-1.91 to -0.39)-0.06 (-0.81 to 0.68)
Day 169: Study Eye-1.5 (-2.3 to -0.6)-0.7 (-1.6 to 0.1)
Day 169: Non-Study Eye-0.5 (-1.3 to 0.3)0.3 (-0.5 to 1.2)
Day 169: Average of Both Eyes-0.99 (-1.79 to -0.19)-0.19 (-0.98 to 0.60)
SecondaryChange From Baseline in Tear Break-up Time

The Mean change from baseline in Tear Break-up Time at all measured time points up to day 169 The CRF collects the time in seconds to first appearance of a random dry spot on the corneal surface for 3 repetitions in each eye. The average time will calculated for each eye averaging the 3 measurements for each eye separately. In case only 2 measurements are available, the average of the 2 measurements will be calculated. In case there is only 1 measurement, that measurement will be used for the analysis.

Time frame:
Day 85, Day 169
Reported as:
Mean · Seconds
Change From Baseline in Tear Break-up Time
SecondsAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 85: Study Eye-0.13 (-0.99 to 0.73)0.18 (-0.67 to 1.04)
Day 85: Non-Study Eye-0.70 (-1.59 to 0.18)-0.12 (-1.01 to 0.76)
Day 85: Average of Both Eyes-0.41 (-1.24 to 0.43)0.09 (-0.74 to 0.92)
Day 169: Study Eye-0.23 (-1.11 to 0.64)-0.32 (-1.19 to 0.56)
Day 169: Non-Study Eye-0.79 (-1.62 to 0.03)-0.62 (-1.46 to 0.21)
Day 169: Average of Both Eyes-0.50 (-1.32 to 0.31)-0.43 (-1.25 to 0.39)
SecondaryChange From Baseline in Unstimulated Salivary Flow

The mean change from baseline in unstimulated whole salivary flow at all measured time points up to Day 169.

Time frame:
Day 85, Day 169
Reported as:
Mean · mL/min
Change From Baseline in Unstimulated Salivary Flow
mL/minAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 850.106 (-0.037 to 0.249)0.158 (0.022 to 0295)
Day 1690.051 (-0.100 to 0.203)0.105 (-0.042 to 0.251)
SecondaryChange From Baseline in Stimulated Salivary Flow

The mean change from baseline in Stimulated whole salivary flow at all measured time points up to Day 169.

Time frame:
Day 85, Day 169
Reported as:
Mean · mL/min
Change From Baseline in Stimulated Salivary Flow
mL/minAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 850.11 (-0.039 to 0.262)0.169 (0.024 to 0.314)
Day 1690.056 (-0.104 to 0.216)0.108 (-0.048 to 0.263)
SecondaryChange From Baseline in Numeric Rating Scale for Mouth Dryness

The mean change from baseline in participant symptoms using the Numeric Rating Scale (NRS) for mouth dryness at all measured time points up to Day 169. The oral and ocular dryness are each assessed by the patients with numeric rating scales from 0 to 10 with 0 representing no dryness and 10 representing maximal dryness

Time frame:
Day 1, 29, 57, 85, 113, 141, 169
Reported as:
Mean · Score on a Scale
Change From Baseline in Numeric Rating Scale for Mouth Dryness
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-0.8 (-8 to 3)-0.5 (-7 to 6)
Day 57-1.3 (-8 to 5)-0.9 (-7 to 6)
Day 85-1.3 (-9 to 4)-1.1 (-6 to 8)
Day 113-1.2 (-9 to 3)-1.3 (-8 to 4)
Day 141-1.3 (-8 to 5)-1.1 (-6 to 6)
Day 169-1.3 (-8 to 3)-1.2 (-6 to 8)
SecondaryChange From Baseline in Numeric Rating Scale for Eye Dryness

The mean change from baseline in patient symptoms using the Numeric Rating Scale (NRS) for eye dryness at all measured time points up to Day 169. The oral and ocular dryness are each assessed by the patients with numeric rating scales from 0 to 10 with 0 representing no dryness and 10 representing maximal dryness

Time frame:
Day 1, 29, 57, 85, 113, 141, 169
Reported as:
Mean · Score on a Scale
Change From Baseline in Numeric Rating Scale for Eye Dryness
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-0.4 (-8 to 5)-0.3 (-6 to 5)
Day 57-0.9 (-7 to 5)-0.6 (-6 to 5)
Day 85-0.9 (-7 to 6)-0.8 (-7 to 8)
Day 113-1.0 (-7 to 7)-1.1 (-8 to 4)
Day 141-0.8 (-7 to 7)-1.0 (-7 to 4)
Day 169-0.9 (-5 to 6)-1.0 (-7 to 5)
SecondaryChange From Baseline in Participant Assessment of Disease Activity

The participant global assessment of disease activity are assessed with visual analog scales. The participant marks a vertical line through a horizontal line, where the beginning of the horizontal line represents the best situation, and the end of the horizontal line represents the very worst situation. The CRF collects the distance in millimeters from the start of the scale that is marked as well as the length of the scale in millimeters. In cases that the length of the scale is in less or more than 100 millimeters, then the participants measurement will be rescaled to the equivalent of 100 millimeters using the formula below: Rescale Measurement in mm = (measurement as reported on CRF in mm/length of the line on CRF in mm) \* 100mm A negative score = participant assessment of disease activity has improved A positive score = participant assessment of disease activity has worsened

Time frame:
Day 29, 57, 85, 113, 141, 169
Reported as:
Mean · Score on VAS 0-100mm scale
Change From Baseline in Participant Assessment of Disease Activity
Score on VAS 0-100mm scaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-4.0 (-9.8 to 1.7)-7.1 (-12.7 to -1.4)
Day 57-7.5 (-13.4 to -1.7)-6.3 (-11.9 to -0.6)
Day 85-10.4 (-16.3 to -4.4)-10.2 (-16.0 to -4.4)
Day 113-8.0 (-14.0 to -2.0)-9.7 (-15.5 to -3.9)
Day 141-5.1 (-11.0 to 0.8)-11.0 (-16.7 to -5.3)
Day 169-10.1 (-16.1 to -4.0)-9.0 (-14.8 to -3.1)
SecondaryChange From Baseline in Physician Global Assessment of Disease Activity

The physician global assessment of disease activity are assessed with visual analog scales. The physician marks a vertical line through a horizontal line, where the beginning of the horizontal line represents the best situation, and the end of the horizontal line represents the very worst situation. The CRF collects the distance in millimeters from the start of the scale that is marked as well as the length of the scale in millimeters. In cases that the length of the scale is in less or more than 100 millimeters, then the participants measurement will be rescaled to the equivalent of 100 millimeters using the formula below: Rescale Measurement in mm = (measurement as reported on CRF in mm/length of the line on CRF in mm) \* 100mm A negative score = physician assessment of disease activity has improved A positive score = physician assessment of disease activity has worsened

Time frame:
Day 29, 57, 85, 113, 141, 169
Reported as:
Mean · Score on VAS 0-100mm Scale
Change From Baseline in Physician Global Assessment of Disease Activity
Score on VAS 0-100mm ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-10.3 (-14.8 to -5.8)-10.5 (-14.9 to -6.1)
Day 57-16.2 (-20.8 to -11.7)-16.7 (-21.1 to -12.3)
Day 85-20.8 (-25.6 to -16.0)-19.4 (-24.0 to -14.7)
Day 113-22.8 (-27.9 to -17.8)-19.8 (-24.6 to -14.9)
Day 141-23.7 (-28.6 to -18.8)-21.7 (-26.5 to -17.0)
Day 169-23.0 (-27.8 to -18.2)-23.7 (-28.3 to -19.0)
SecondaryChange From Baseline in Patient Fatigue

The mean change from baseline in patient fatigue using Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue assessment of disease activity at all measured time points up to Day 169. PROMIS Fatigue instruments 10 Questions ranging from a score 0 to 40. Sum of the values gives you the raw sum. The raw is inputted into this formula to give you the raw score: Raw Score = (Raw sum\*number of items on the short form)/(Number of items that were actually answered) Raw score is translated to a T-Score using a table. T-Score is used as the final score. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. The standardized T-score is reported as the final score for each participant. A negative T Score = Better Prognosis A positive T Score = Worse prognosis

Time frame:
Day 29, 57, 85, 113, 141, 169
Reported as:
Mean · T-Score
Change From Baseline in Patient Fatigue
T-ScoreAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 29-3.08 (-5.22 to -0.95)-3.99 (-6.09 to -1.88)
Day 57-4.12 (-6.27 to -1.97)-4.02 (-6.12 to -1.91)
Day 85-4.85 (-7.05 to -2.64)-5.48 (-7.64 to -3.32)
Day 113-4.17 (-6.37 to -1.97)-5.32 (-7.48 to -3.17)
Day 141-4.84 (-7.06 to -2.62)-5.68 (-7.85 to -3.52)
Day 169-5.56 (-7.83 to -3.28)-5.59 (-7.82 to -3.37)
SecondaryChange From Baseline in Female Sexual Function Using the Female Sexual Function Index (FSFI)

For the FSFI, is a 19 item instrument used for assessing key dimensions of female sexual function over the past 4 weeks with 6 domains being analyzed. The specific domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) analyzed in the FSFI are scored on a scale ranging from 0 to 5, with higher scores indicating better performance. Domain scores are calculated by summing the scores of the individual questions that make up the domain and multiplying the sum by the factor in the table below. The full scale score is the sum of the six domain scores. Full Scale Score range: 2.0(minimum score) - 36.0 (maximum score) Negative Score = Reduced functioning Positive Score = Improved functioning

Time frame:
Day 85, Day 169
Reported as:
Mean · Scores on a Scale
Change From Baseline in Female Sexual Function Using the Female Sexual Function Index (FSFI)
Scores on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 85-2.44 (-5.67 to 0.78)-1.56 (-4.90 to 1.77)
Day 169-2.32 (-5.73 to 1.09)-1.87 (-5.42 to 1.68)
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36)

The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement

Time frame:
Day 85, Day 169
Reported as:
Mean · Score on a Scale
Change From Baseline in 36-item Short Form Health Survey (SF-36)
Score on a ScaleAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 85: Physical Function1.908 (-0.240 to 4.056)1.523 (-0.568 to 3.614)
Day 85: Role Physical5.248 (3.112 to 7.383)4.416 (2.321 to 6.511)
Day 85: Bodily Pain3.200 (0.910 to 5.490)3.721 (1.464 to 5.978)
Day 85: General Health4.042 (1.938 to 6.146)3.409 (1.363 to 5.456)
Day 85: Vitality3.827 (1.269 to 6.384)3.859 (1.335 to 6.382)
Day 85: Social Functioning3.020 (0.296 to 5.744)4.771 (2.117 to 7.426)
Day 85: Role-Emotional3.024 (0.214 to 5.834)4.834 (2.093 to 7.576)
Day 85: Mental Health2.942 (0.458 to 5.425)2.287 (-0.135 to 4.709)
Day 85: Physical component Summary3.430 (1.615 to 5.244)2.686 (0.904 to 4.468)
Day 85: Mental component Summary2.693 (0.160 to 5.226)3.672 (1.208 to 6.136)
Day 169: Physical Function2.927 (0.593 to 5.261)1.742 (-0.505 to 3.989)
Day 169: Role-Physical5.853 (3.756 to 7.949)4.626 (2.604 to 6.649)
Day 169: Bodily Pain3.842 (1.432 to 6.252)3.458 (1.114 to 5.801)
Day 169: General Health3.880 (1.700 to 6.060)3.764 (1.665 to 5.862)
Day 169: Vitality3.742 (1.160 to 6.324)4.523 (2.005 to 7.041)
Day 169: Social functioning4.125 (1.320 to 6.929)4.471 (1.773 to 7.169)
Day 169: Role-Emotional4.653 (1.943 to 7.364)4.930 (2.334 to 7.526)
Day 169: Mental Health2.375 (-0.116 to 4.866)2.972 (0.581 to 5.363)
Day 169: Physical Component Summary3.998 (2.045 to 5.951)2.650 (0.756 to 4.543)
Day 169: Mental Component Summary2.940 (0.368 to 5.512)4.112 (1.648 to 6.577)
SecondaryGeometric Mean of Trough Concentration (Cmin) of Abatacept

Geometric mean of trough concentration (Cmin) of abatacept at all measured time points.

Time frame:
Day 29, 85, 113, 141, 169
Reported as:
Geometric mean · µg/mL
Geometric Mean of Trough Concentration (Cmin) of Abatacept
µg/mLAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Day 2921.401 ± 36—
Day 8527.543 ± 38.4—
Day 11325.567 ± 42.1—
Day 14125.870 ± 40.8—
Day 16924.522 ± 42.7—
SecondaryPercentage of Participants With a Positive Antibody Response

Percentage of participants with at least one positive immunogenicity response up to Day 169 and during 3 months follow up (for participants who discontinue during the 6-months double-blind).

Time frame:
Day 85 db, day 169 db, post treatment day 85
Reported as:
Number · Percentage
Percentage of Participants With a Positive Antibody Response
PercentageAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Study Day 1691.2—
Post Treatment Day 85 (DB)0—
Post Treatment Day 169 (DB)0—
SecondarySummary of Adverse Events: Double Blind Period

Percentage of participants with adverse events, deaths, serious adverse events and adverse events leading to discontinuation

Time frame:
Day 1 up to first dose of Open Label Treatment Period (OLTP) abatacept or up to 56 post last dose in double -blind for those not in OL.
Reported as:
Number · Percentage
Summary of Adverse Events: Double Blind Period
PercentageAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Adverse Events (AEs)85.971.6
Deaths01.1
Serious Adverse Events9.83.2
Discontinuation due to AEs3.32.1
SecondaryLaboratory Marked Abnormalities: Double Blind Period

Laboratory values meeting the marked abnormality criteria

Time frame:
Day 1 up to first dose of OL abatacept or up to 56 post last dose in double -blind for those not in OL.
Reported as:
Number · Percentage
Laboratory Marked Abnormalities: Double Blind Period
PercentageAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment Period
Hematocrit HighNANA
Hematocrit Low00
Hemoglobin HighNANA
Hemoglobin Low00
Platelet count High00
Platelet count low00
Leukocytes high1.10
Leukocytes low12.18.4
Basophils high00
Basophils LowNANA
Eosinophils High4.41.1
Eosinophils LowNANA
lymphocytes high00
lymphocytes low9.914.7
Monocytes high00
Monocytes LowNANA
Neutrophils+Bands HighNANA
Neutrophils+Bands Low6.61.1
Alanine Aminotransferase High1.12.1
Alkaline Phosphatase HIgh00
Aspartate Aminotransferase High1.13.2
Bilirubin, Total High00
G-Glutamyl Transferase High6.61.1
Blood Urea Nitrogen High1.11.1
Creatinine High00
Calcium High00
Calcium Low1.10
Chloride High00
Chloride Low1.10
Phosphorus High00
Phosphorus Low01.1
Potassium High00
Potassium Low1.10
Sodium High01.1
Sodium Low2.20
Glucose, Serum High01.1
Glucose, Serum Low2.25.3
Albumin HighNANA
Albumin Low2.21.1
Protein, Total High2.23.2
Protein, Total Low1.10
Creatine Kinase High04.2
Blood, Urine High14.39.5
Blood, Urine LowNANA
Glucose, Urine High00
Glucose, Urine LowNANA
Protein, Urine High2.23.2
SecondaryPercentage of Participants With a Positive Antibody Response in the Cumulative Abatacept Period

Percentage of participants with at least one positive immunogenicity response On Day 365 (end of Open label treatment period) and day 85 post open label follow up period.

Time frame:
Day 365, post open label treatment day 85
Reported as:
Number · Percentage
Percentage of Participants With a Positive Antibody Response in the Cumulative Abatacept Period
PercentageAbatacept - Cumulative Open Label Treatment Period
Study Day 3652.1
Post Treatment Day 85 (OL)43.2
SecondarySummary of Adverse Events: Cumulative Abatacept Period

Percentage of participants with adverse events, deaths, serious adverse events and adverse events leading to discontinuation

Time frame:
Day 365 and 3 months of follow up approximately 450 Days
Reported as:
Number · Percentage
Summary of Adverse Events: Cumulative Abatacept Period
PercentageCumulative Treatment Period
Adverse Events (AEs)78.7
Deaths0.6
Serious Adverse Events (SAEs)14.6
Discontinuation due to AEs5.6
Related Serious Adverse Events3.4
Discontinued due to SAEs3.4
Related AEs40.4
SecondaryLaboratory Marked Abnormalities: Cumulative Abatacept Period

Laboratory values meeting the marked abnormality criteria

Time frame:
Day 365 and 3 months of follow up approximately 450 Days
Reported as:
Number · Percentage
Laboratory Marked Abnormalities: Cumulative Abatacept Period
PercentageCumulative Open Label Treatment Period
Hematocrit HighNA
Hematocrit Low0
Hemoglobin HighNA
Hemoglobin Low0.6
Platelet count High0
Platelet count low0.6
Leukocytes high0.6
Leukocytes low18.6
Basophils high0.6
Basophils LowNA
Eosinophils High5.6
Eosinophils LowNA
lymphocytes high0
lymphocytes low12.4
Monocytes high0
Monocytes LowNA
Neutrophils+Bands HighNA
Neutrophils+Bands Low7.3
Alanine Aminotransferase High1.7
Alkaline Phosphatase HIgh0.6
Aspartate Aminotransferase High1.1
Bilirubin, Total High0
G-Glutamyl Transferase High5.6
Blood Urea Nitrogen High1.7
Creatinine High0.6
Calcium High0
Calcium Low1.1
Chloride High0
Chloride Low1.1
Phosphorus High0.6
Phosphorus Low1.1
Potassium High0.6
Potassium Low0.6
Sodium High0.6
Sodium Low1.7
Glucose, Serum High0.6
Glucose, Serum Low5.1
Albumin HighNA
Albumin Low1.7
Protein, Total High4.0
Protein, Total Low0.6
Creatine Kinase High2.3
Blood, Urine High14.7
Blood, Urine LowNA
Glucose, Urine High0
Glucose, Urine LowNA
Protein, Urine High5.6
WBC, Urine High100.0

Adverse events

Collected over First dose to 169 days past open label period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept - Double Blind Treatment Period0/92 (0%)9/92 (9.8%)47/92 (51.1%)
Placebo - Double Blind Treatment Period1/95 (1.1%)3/95 (3.2%)40/95 (42.1%)
Abatacept - Open Label Treatment Period1/178 (0.6%)19/178 (10.7%)61/165 (37%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment PeriodAbatacept - Open Label Treatment Period
Device dislocationProduct Issues0/920/952/165
Prinzmetal anginaCardiac disorders1/920/950/165
Intestinal obstructionGastrointestinal disorders1/920/950/165
Hepatic cyst rupturedHepatobiliary disorders1/920/950/165
Anaphylactoid reactionImmune system disorders1/920/950/165
Drug hypersensitivityImmune system disorders1/920/950/165
Pneumonia bacterialInfections and infestations1/920/950/165
ArthropathyMusculoskeletal and connective tissue disorders1/920/950/165
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/920/950/165
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/920/950/165
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAbatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment PeriodAbatacept - Open Label Treatment Period
NasopharyngitisInfections and infestations11/9218/9522/165
DiarrhoeaGastrointestinal disorders11/924/959/165
HeadacheNervous system disorders10/929/959/165
NauseaGastrointestinal disorders9/924/951/165
Upper respiratory tract infectionInfections and infestations9/927/9515/165
Urinary tract infectionInfections and infestations6/928/9512/165
Oropharyngeal painRespiratory, thoracic and mediastinal disorders6/921/952/165
Abdominal pain upperGastrointestinal disorders5/920/954/165
MyalgiaMusculoskeletal and connective tissue disorders5/922/954/165
InsomniaPsychiatric disorders5/921/952/165

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Abatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment PeriodTotal
Mean51.2 ± 12.352.9 ± 13.552.0 ± 12.9
Age, Customized
Age, Customized(Participants)Abatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment PeriodTotal
< 65 years8073153
≥ 65 years122234
≤ 50 years424284
> 50 years5053103
Sex: Female, Male
Sex: Female, Male(Participants)Abatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment PeriodTotal
Female8592177
Male7310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment PeriodTotal
Hispanic or Latino257
Not Hispanic or Latino101323
Unknown or Not Reported8077157
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abatacept - Double Blind Treatment PeriodPlacebo - Double Blind Treatment PeriodTotal
American Indian or Alaska Native000
Asian212344
Native Hawaiian or Other Pacific Islander000
Black or African American10919
White6060120
More than one race000
Unknown or Not Reported134
08

Study locations

71 sites
  • St. Jude Hospital Yorba Linda
    Fullerton, California 92835, United States
  • Riverside Medical Clinic
    Riverside, California 92506, United States
  • Colorado Arthritis Associates
    Lakewood, Colorado 80228, United States
  • North Georgia Rheumatology Group
    Lawrenceville, Georgia 30046, United States
  • Intermountain Research Center Inc.
    Boise, Idaho 83702, United States
  • Johns Hopkins University
    Baltimore, Maryland 21224, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • St. Paul Rheumatology, P.A.
    Eagan, Minnesota 55121, United States
  • Northwell Health
    Great Neck, New York 11021, United States
  • Local Institution
    Charlotte, North Carolina 28203, United States
  • Joint and Muscle Medical Care and Research Institute (JMMCRI)
    Charlotte, North Carolina 28204, United States
  • Duke Clinical Research Unit, Duke Univ Med Ctr, Duke South
    Durham, North Carolina 27710, United States
  • Health Research Of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • East Penn Rheumatology
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635-8406, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Scott Zashin Inc.
    Dallas, Texas 75231, United States
  • Organizacion Medica De Investigacion S.A. (Omi)
    Capital Federal, Buenos Aires 1015, Argentina
  • Local Institution
    Ciudad Autonoma Beunos Aires, Buenos Aires 1431, Argentina
  • Instituto de Asistencia Reumatologica Integral
    San Fernando, Buenos Aires 1646, Argentina
  • Local Institution
    Buenos Aires, 1428, Argentina
  • Consultorios Medicos Dr. Catalan Pellet
    Caba, 1111, Argentina
  • Instituto Reumatologico Strusberg
    Cordoba, 5000, Argentina
  • Local Institution
    Maroochydore, Queensland 4558, Australia
  • Local Institution
    Woodville, South Australia 5011, Australia
  • Local Institution
    Camberwell, Victoria 3124, Australia
  • Local Institution
    Nedlands, Western Australia 6009, Australia
  • Local Institution
    Savaldor, Bahia 40150-150, Brazil
  • Local Institution
    Vitoria, ES 29055-450, Brazil
  • Local Institution
    Porto Alegre, RIO Grande DO SUL 90480-000, Brazil
  • Local Institution
    Sao Paulo, 04032-060, Brazil
  • Revmatologie s.r.o.
    Brno, 638 00, Czechia
  • Local Institution
    Bordeaux, 33075, France
  • Local Institution
    Le Kremlin Bicetre Cedex, 94275, France
  • Hopital Europeen
    Marseille, 13003, France
  • Local Institution
    Marseille, 13008, France
  • Hopital Lapeyronie
    Montpellier Cedex 5, 34295, France
  • Local Institution
    Paris Cedex 10, 75475, France
  • Local Institution
    Strasbourg, 67098, France
  • Medizinische Universitaetsklinik Freiburg
    Freiburg, 79106, Germany
  • Med Hochschule Hannover
    Hannover, 30625, Germany
  • Krankenhaus St. Josef
    Wuppertal, 42105, Germany
  • Local Institution
    Milano, 20122, Italy
  • Ospedale Santa Maria Della Misericordia
    Udine, 33100, Italy
  • Local Institution
    Nagoya-shi, Aichi 4578511, Japan
  • Local Institution
    Kitakyushu-shi, Fukuoka 8078555, Japan
  • Local Institution
    Sapporo-shi, Hokkaido 0608648, Japan
  • Local Institution
    Nishinomiya-shi, Hyogo 6638501, Japan
  • Local Institution
    Tsukuba-shi, Ibaraki 3050005, Japan
  • Local Institution
    Kamigyo-ku, Kyoto 602-8566, Japan
  • Local Institution
    Sendai-shi, Miyagi 9808574, Japan
  • Local Institution
    Nagasaki-shi, Nagasaki 8528501, Japan
  • Local Institution
    Kurashiki-shi, Okayama 7108522, Japan
  • Local Institution
    Hamamatsu-shi, Shizuoka 4313192, Japan
  • Local Institution
    Chuo-ku, Tokyo 1048560, Japan
  • Local Institution
    Itabashi-ku, Tokyo 1738610, Japan
  • Local Institution
    Meguro-ku, Tokyo 1538515, Japan
  • Local Institution
    Shinjuku-Ku, Tokyo 1608582, Japan
  • Local Institution
    Daegu, 42472, Korea, Republic of
  • Local Institution
    Gwangju, 61469, Korea, Republic of
  • Local Institution
    Seoul, 06591, Korea, Republic of
  • Consultorio Medico de Reumatologia Dr.Jesus Alberto Lopez Garcia
    Leon, Guanajuato 37000, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo LEON 64460, Mexico
  • Local Institution
    Distrito Federal, 14080, Mexico
  • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.
    San Luis Potosi, 78213, Mexico
  • Local Institution
    San Juan, 00909, Puerto Rico
  • Local Institution
    San Juan, 00918, Puerto Rico
  • Local Institution
    Solna, 171 64, Sweden
  • Local Institution
    Uppsala, 751 85, Sweden
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Aug 2018, 20 months.

Results were first posted in Jan 2020, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2016
First posted
Sep 26, 2016
StartActual
Dec 6, 2016
Primary completionActual
Aug 7, 2018
CompletionActual
Jul 23, 2019
Results first posted
Jan 2, 2020
Last update
Aug 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02915159
Responsible party
Sponsor
First posted
Sep 26, 2016
Start date
Dec 6, 2016
Primary completion
Aug 7, 2018
Completion
Jul 23, 2019
Results posted
Jan 2, 2020
Last update
Aug 10, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion